Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 40

Sort by

Sort Order Select

Journal Articles

In Vivo Inhibition of Dipeptidyl Peptidase 4 Allows Measurement of GLP-1 Secretion in Mice

Mark M. Smits, Katrine D. Galsgaard, Sara Lind Jepsen, Nicolai Wewer Albrechtsen, Bolette Hartmann, Jens J. Holst

Diabetes 2024;73(5):671–681

https://doi.org/10.2337/db23-0848

Published: 31 January 2024

View article titled, In Vivo Inhibition of Dipeptidyl Peptidase 4 Allows Measurement of GLP-1 Secretion in Mice

Meeting Abstracts

462-P: DPP-4 Deficiency Suppresses the Progression of Atherosclerosis via Inducing M2 Macrophage Polarization

YUQI ZHOU, TAKESHI MATSUMURA, YOSHITAKA YAGI, TOMOAKI YOSHINAGA, TAKAFUMI SENOKUCHI, NORIO ISHII, TATSUYA KONDO, EIICHI ARAKI

Diabetes 2023;72(Supplement_1):462-P

https://doi.org/10.2337/db23-462-P

Published: 20 June 2023

View article titled, 462-P: DPP-4 Deficiency Suppresses the Progression of Atherosclerosis via Inducing M2 Macrophage Polarization

Journal Articles

Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study

Jennifer E. Nyland, Nazia T. Raja-Khan, Kerstin Bettermann, Philippe A. Haouzi, Douglas L. Leslie, Jennifer L. Kraschnewski, Leslie J. Parent, Patricia Sue Grigson

Diabetes 2021;70(12):2903–2916

https://doi.org/10.2337/db21-0385

Published: 27 September 2021

View article titled, Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study

Meeting Abstracts

1783-P: Effects of DPP-4 Inhibition on the Enteroinsular Axis in Pancreatic Insufficient Cystic Fibrosis

SABA SHEIKH, ANDREA KELLY, DARKO STEFANOVSKI, AMY J. PELECKIS, SARAH NYIRJESY, JACK N. EIEL, ANIKET SIDHAYE, DIVA D. DE LEON, DENIS HADJILIADIS, RONALD C. RUBENSTEIN, MICHAEL R. RICKELS

Diabetes 2020;69(Supplement_1):1783-P

https://doi.org/10.2337/db20-1783-P

Published: 01 June 2020

View article titled, 1783-P: Effects of DPP-4 Inhibition on the Enteroinsular Axis in Pancreatic Insufficient Cystic Fibrosis

Meeting Abstracts

2054-P: Combination of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor and Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Substantially Protects Pancreatic ß-Cells Especially in Early Phase of Diabetes Rather than Advanced Phase

YOSHIRO FUSHIMI, ATSUSHI OBATA, JUNPEI SANADA, YUKA NOGAMI, TOMOKO IKEDA, YOSHIYUKI OBATA, MASASHI SHIMODA, SHUHEI NAKANISHI, TOMOATSU MUNE, KOHEI KAKU, HIDEAKI KANETO

Diabetes 2020;69(Supplement_1):2054-P

https://doi.org/10.2337/db20-2054-P

Published: 01 June 2020

View article titled, 2054-P: Combination of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor and Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Substantially Protects Pancreatic ß-Cells Especially in Early Phase of Diabetes Rather than Advanced Phase

Meeting Abstracts

710-P: Serum DPP-4 Protein Is Decreased upon Consuming an Isocaloric High Saturated Fat Diet and Genetically Determined in Healthy Human Twins

MICHAEL KRUSE, ANNE-CATHRIN OST, SILKE HORNEMANN, DANIELA HOFFMANN, TURID FRAHNOW, ANDREAS BUSJAHN, ANDREAS F. PFEIFFER

Diabetes 2020;69(Supplement_1):710-P

https://doi.org/10.2337/db20-710-P

Published: 01 June 2020

View article titled, 710-P: Serum DPP-4 Protein Is Decreased upon Consuming an Isocaloric High Saturated Fat Diet and Genetically Determined in Healthy Human Twins

Meeting Abstracts

1092-P: Treatment Changes Post–Second-Line Medication Initiation, a Real-World Retrospective Cohort Study

SANYA PASRICHA, MANISHA CHERUPALLY, ELEENA KOEP, RONALD T. ACKERMANN, CASSANDRA AIKMAN, ANDREW J. COOPER, MATTHEW O’BRIEN, AMISHA WALLIA, DAVID T. LISS, EMILY D. PARKER

Diabetes 2020;69(Supplement_1):1092-P

https://doi.org/10.2337/db20-1092-P

Published: 01 June 2020

View article titled, 1092-P: Treatment Changes Post–Second-Line Medication Initiation, a Real-World Retrospective Cohort Study

Meeting Abstracts

1142-P: Comparison of Hospitalization for Heart Failure (HHF) among Patients with Type 2 Diabetes Mellitus (T2DM) and Macroalbuminuria Initiated on Canagliflozin (CANA) or a DPP-4

DOMINIC PILON, MICHAEL DURKIN, AMEUR MANCEUR, ISABELLE GHELERTER, MARIE-HÉL LAFEUILLE, PATRICK LEFEBVRE

Diabetes 2020;69(Supplement_1):1142-P

https://doi.org/10.2337/db20-1142-P

Published: 01 June 2020

View article titled, 1142-P: Comparison of Hospitalization for Heart Failure (HHF) among Patients with Type 2 Diabetes Mellitus (T2DM) and Macroalbuminuria Initiated on Canagliflozin (CANA) or a DPP-4

Meeting Abstracts

1229-P: Dapagliflozin Improves Liver Dysfunction in Parallel with a Decrease in Serum Soluble DPP-4/CD26 Level in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease

KANAKO KATO, YOSHIMASA ASO, TERUO JOJIMA, TOSHIE IIJIMA, ISAO USUI

Diabetes 2019;68(Supplement_1):1229-P

https://doi.org/10.2337/db19-1229-P

Published: 01 June 2019

View article titled, 1229-P: Dapagliflozin Improves Liver Dysfunction in Parallel with a Decrease in Serum Soluble DPP-4/CD26 Level in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease

Meeting Abstracts

267-LB: Diabetes-induced Insulin Resistance and DPP-4 Activity Can Be Alleviated through the Reduction of M1 Polarization of Adipose Tissue

LEE-WEI CHEN

Diabetes 2019;68(Supplement_1):267-LB

https://doi.org/10.2337/db19-267-LB

Published: 01 June 2019

View article titled, 267-LB: Diabetes-induced Insulin Resistance and DPP-4 Activity Can Be Alleviated through the Reduction of M1 Polarization of Adipose Tissue

Journal Articles

The Dipeptidyl Peptidase 4 Substrate CXCL12 Has Opposing Cardiac Effects in Young Mice and Aged Diabetic Mice Mediated by Ca²⁺ Flux and Phosphoinositide 3-Kinase γ

Sri N. Batchu, Karina Thieme, Farigol H. Zadeh, Tamadher A. Alghamdi, Veera Ganesh Yerra, Mitchell J. Hadden, Syamantak Majumder, M. Golam Kabir, Bridgit B. Bowskill, Danyal Ladha, Anthony O. Gramolini, Kim A. Connelly, Andrew Advani

Diabetes 2018;67(11):2443–2455

https://doi.org/10.2337/db18-0410

Published: 27 August 2018

View article titled, The Dipeptidyl Peptidase 4 Substrate CXCL12 Has Opposing Cardiac Effects in Young Mice and Aged Diabetic Mice Mediated by Ca<sup>2+</sup> Flux and Phosphoinositide 3-Kinase γ

Includes: Supplementary data

Meeting Abstracts

The New Paradigm of Diabetes Care

SAAD SAKKAL

Diabetes 2018;67(Supplement_1):2270-PUB

https://doi.org/10.2337/db18-2270-PUB

Published: 01 July 2018

View article titled, The New Paradigm of Diabetes Care

Meeting Abstracts

Exploring Hepatic Safety of the Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Vildagliptin in a Real-World Setting

RACHAEL WILLIAMS, WOLFGANG KOTHNY, CARMEN SERBAN, PÄIVI M. PALDÁNIUS, RAYMOND SCHLIENGER

Diabetes 2018;67(Supplement_1):1185-P

https://doi.org/10.2337/db18-1185-P

Published: 01 July 2018

View article titled, Exploring Hepatic Safety of the Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Vildagliptin in a Real-World Setting

Meeting Abstracts

Empagliflozin and Linagliptin Administered in Combination or as Serial Add-On Therapy Decreases Macrovascular and Microvascular Stiffening and Microalbuminuria in a Mouse Model of Diabetic Nephropathy

ANNAYYA R. AROOR, JAVAD HABIBI, GUANGHONG JIA, THOMAS KLEIN, ERIC MAYOUX, VINCENT DEMARCO

Diabetes 2018;67(Supplement_1):2009-P

https://doi.org/10.2337/db18-2009-P

Published: 01 July 2018

View article titled, Empagliflozin and Linagliptin Administered in Combination or as Serial Add-On Therapy Decreases Macrovascular and Microvascular Stiffening and Microalbuminuria in a Mouse Model of Diabetic Nephropathy

Journal Articles

DPP-4 Inhibitors Improve Diabetic Wound Healing via Direct and Indirect Promotion of Epithelial-Mesenchymal Transition and Reduction of Scarring

Min Long, Leiqin Cai, Wenjie Li, Linlin Zhang, Shaodong Guo, Rui Zhang, Yi Zheng, Xiufei Liu, Min Wang, Xianli Zhou, Hui Wang, Xing Li, Ling Li, Zhiming Zhu, Gangyi Yang, Hongting Zheng

Diabetes 2018;67(3):518–531

https://doi.org/10.2337/db17-0934

Published: 18 December 2017

View article titled, DPP-4 Inhibitors Improve Diabetic Wound Healing via Direct and Indirect Promotion of Epithelial-Mesenchymal Transition and Reduction of Scarring

Includes: Supplementary data

Journal Articles

DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization

Fen Zhuge, Yinhua Ni, Mayumi Nagashimada, Naoto Nagata, Liang Xu, Naofumi Mukaida, Shuichi Kaneko, Tsuguhito Ota

Diabetes 2016;65(10):2966–2979

https://doi.org/10.2337/db16-0317

Published: 21 July 2016

View article titled, DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization

Includes: Supplementary data

Journal Articles

DPP-4 Inhibition and the Known Unknown

Michael Horowitz, Tongzhi Wu, Adam M. Deane, Karen L. Jones, Christopher K. Rayner

Diabetes 2016;65(8):2124–2126

https://doi.org/10.2337/dbi16-0023

Published: 12 July 2016

View article titled, DPP-4 Inhibition and the Known Unknown

Journal Articles

In This Issue of Diabetes

Diabetes 2016;65(8):2103–2104

https://doi.org/10.2337/db16-ti08

Published: 12 July 2016

View article titled, In This Issue of <em>Diabetes</em>

Journal Articles

Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist

Michael A. Nauck, Joachim Kind, Lars D. Köthe, Jens J. Holst, Carolyn F. Deacon, Matthias Broschag, Yan Ling He, Lise Kjems, James Foley

Diabetes 2016;65(8):2440–2447

https://doi.org/10.2337/db16-0107

Published: 05 April 2016

View article titled, Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist

Includes: Supplementary data

Journal Articles

Dipeptidyl Peptidase-4 Inhibition Ameliorates Western Diet–Induced Hepatic Steatosis and Insulin Resistance Through Hepatic Lipid Remodeling and Modulation of Hepatic Mitochondrial Function

Annayya R. Aroor, Javad Habibi, David A. Ford, Ravi Nistala, Guido Lastra, Camila Manrique, Merlow M. Dunham, Kaitlin D. Ford, John P. Thyfault, Elizabeth J. Parks, James R. Sowers, R. Scott Rector

Diabetes 2015;64(6):1988–2001

https://doi.org/10.2337/db14-0804

Published: 20 January 2015

View article titled, Dipeptidyl Peptidase-4 Inhibition Ameliorates Western Diet–Induced Hepatic Steatosis and Insulin Resistance Through Hepatic Lipid Remodeling and Modulation of Hepatic Mitochondrial Function

NARROW

In Vivo Inhibition of Dipeptidyl Peptidase 4 Allows Measurement of GLP-1 Secretion in Mice

462-P: DPP-4 Deficiency Suppresses the Progression of Atherosclerosis via Inducing M2 Macrophage Polarization

Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study

1783-P: Effects of DPP-4 Inhibition on the Enteroinsular Axis in Pancreatic Insufficient Cystic Fibrosis

2054-P: Combination of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor and Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Substantially Protects Pancreatic ß-Cells Especially in Early Phase of Diabetes Rather than Advanced Phase

710-P: Serum DPP-4 Protein Is Decreased upon Consuming an Isocaloric High Saturated Fat Diet and Genetically Determined in Healthy Human Twins

1092-P: Treatment Changes Post–Second-Line Medication Initiation, a Real-World Retrospective Cohort Study

1142-P: Comparison of Hospitalization for Heart Failure (HHF) among Patients with Type 2 Diabetes Mellitus (T2DM) and Macroalbuminuria Initiated on Canagliflozin (CANA) or a DPP-4

1229-P: Dapagliflozin Improves Liver Dysfunction in Parallel with a Decrease in Serum Soluble DPP-4/CD26 Level in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease

267-LB: Diabetes-induced Insulin Resistance and DPP-4 Activity Can Be Alleviated through the Reduction of M1 Polarization of Adipose Tissue

The Dipeptidyl Peptidase 4 Substrate CXCL12 Has Opposing Cardiac Effects in Young Mice and Aged Diabetic Mice Mediated by Ca²⁺ Flux and Phosphoinositide 3-Kinase γ

The New Paradigm of Diabetes Care

Exploring Hepatic Safety of the Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Vildagliptin in a Real-World Setting

Empagliflozin and Linagliptin Administered in Combination or as Serial Add-On Therapy Decreases Macrovascular and Microvascular Stiffening and Microalbuminuria in a Mouse Model of Diabetic Nephropathy

DPP-4 Inhibitors Improve Diabetic Wound Healing via Direct and Indirect Promotion of Epithelial-Mesenchymal Transition and Reduction of Scarring

DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization

DPP-4 Inhibition and the Known Unknown

In This Issue of Diabetes

Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist

Dipeptidyl Peptidase-4 Inhibition Ameliorates Western Diet–Induced Hepatic Steatosis and Insulin Resistance Through Hepatic Lipid Remodeling and Modulation of Hepatic Mitochondrial Function

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only